Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 3/2004

01-03-2004 | Neonatal and Pediatric Intensive Care

Terlipressin for catecholamine-resistant septic shock in children

Authors: Antonio Rodríguez-Núñez, Manuel Fernández-Sanmartín, Federico Martinón-Torres, Natalia González-Alonso, José María Martinón-Sánchez

Published in: Intensive Care Medicine | Issue 3/2004

Login to get access

Abstract

Objective

To report the effects of terlipressin treatment in four paediatric patients with catecholamine-resistant hypotensive septic shock.

Design and setting

Case report in the pediatric intensive care unit of a university hospital.

Patients

Four children with severe septic shock and hypotension resistant to high doses of norepinephrine and other cathecolamines.

Interventions

Terlipressin was added to the standard treatment, by intravenous bolus at a dose of 0.02 mg/kg every 4 h during a maximum time of 3 days.

Measurement and results

In all cases, terlipressin induced a rapid and sustained improvement in mean arterial pressure, which allowed the lessening or even withdrawal of norepinephrine infusion. No related adverse effects were detected.

Conclusion

Terlipressin might be considered, at least as a rescue therapy, for hypotension resistant to catecholamines in children with septic shock. Further studies are needed to confirm the beneficial effects found in our patients. The optimal administration schedule remains to be elucidated.
Literature
1.
Carcillo JA, Fields AI (2002) Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 30:1365–1378PubMed
2.
Malay MB, Ashton RCJ, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–705PubMed
3.
O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210CrossRefPubMed
4.
Dünser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR (2001) The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93:7–13PubMed
5.
Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyla WA (2001) Hemodynamic metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493PubMed
6.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421PubMed
7.
Asfar P (2003) Terlipressin in chronic hyperdynamic endotoxic shock: Is it safe? Intensive Care Med 29:154–155PubMed
8.
Ioannou G, Doust J, Rockey DC (2003) Terlipressin for acute esophageal variceal hemorrhage (Cochrane Review). Cochrane Database Syst Rev CD002147
9.
Moreau R (2002) Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 17:739–747CrossRefPubMed
10.
Landry D, Oliver J (2001) The pathogenesis of the vasodilatory shock. N Engl J Med 345:588–595PubMed
11.
Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alesandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilatation of septic shock. Circulation 95:1122–1125PubMed
12.
De Keulenaer BL, Stephens DP (2003) Comment on “Terlipressin in chronic hyperdynamic endotoxic shock: Is it safe?” by P. Asfar. Intensive Care Med 29:854PubMed
13.
Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756–1760PubMed
14.
Dünser MW, Mayr AJ, Tür A, Pajk W, Barbara F, Knotzer J, Ulmer H, Hasibeder WR (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394–1398CrossRefPubMed
15.
Westphal M, Bone HG, Van Aken H, Sielenkämper AW (2002) Terlipressin for haemoynamic support in septic patients: a double-edged sword? Lancet 360:1250–1251CrossRef
Metadata
Title
Terlipressin for catecholamine-resistant septic shock in children
Authors
Antonio Rodríguez-Núñez
Manuel Fernández-Sanmartín
Federico Martinón-Torres
Natalia González-Alonso
José María Martinón-Sánchez
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 3/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-003-2114-3

Other articles of this Issue 3/2004

Intensive Care Medicine 3/2004 Go to the issue

Erratum

Abstracts of the 16th Annual Congress of the European Society of Intensive Care Medicine, Amsterdam, Netherlands

Experimental

Expression of nitric oxide synthase, aquaporin 1 and aquaporin 5 in rat after bleomycin inhalation

Experimental

Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs

Review

Permissive hypercapnia — role in protective lung ventilatory strategies

Neonatal and Pediatric Intensive Care

Relation of cerebral tissue oxygenation index to central venous oxygen saturation in children

Correspondence

Lactic acidosis: An early marker of propofol infusion syndrome?